
Prescription Acne Treatment for Teens | AKLIEF® (trifarotene) Cream
AKLIEF® (trifarotene) Cream, 0.005%, an innovative teen prescription acne treatment for face, chest, shoulders & back. Get clearer skin. See Safety Info
Prescribed Acne Medication for Teens | AKLIEF® (trifarotene) Cream
AKLIEF Cream is a prescription retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. 3 AKLIEF Cream may help reduce inflammatory acne and …
Acne Treatment Before & After Results | AKLIEF® (trifarotene) Cream
AKLIEF® (trifarotene) Cream, 0.005 acne treatment results for face, chest, shoulders & back. View AKLIEF® Cream before & after pictures. See safety info
Acne Vulgaris Treatment | AKLIEF® (trifarotene) Cream HCP
Treat patients with AKLIEF® (trifarotene) Cream, 0.005%, a topical prescription cream proven effective on facial & truncal acne vulgaris. See safety Info
Prescribing Information | AKLIEF® (trifarotene) Cream
Read AKLIEF® (trifarotene) Cream, 0.005 prescribing information including indications, usage, dosage, administration, warnings & more. See safety info
About AKLIEF® Cream | AKLIEF® (trifarotene) Cream HCP
AKLIEF® (trifarotene) Cream, 0.005% contains the first retinoid molecule to target RAR-γ in treating facial & truncal acne vulgaris. See safety Info
Patient Savings Card | AKLIEF® (trifarotene) Cream
Download your Savings Card and you may receive instant savings on your AKLIEF Cream prescription and refills.* If approved, the card can act like an AKLIEF Cream savings coupon to …
Treating Teen Acne | AKLIEF® (trifarotene) Cream
Download discussion guide for talking to dermatologist about teen acne treatment. Learn how to use AKLIEF® (trifarotene) Cream, 0.005%. See safety info
Acne Facts & Skincare for Teens | AKLIEF® (trifarotene) Cream
Get acne skincare tips. Learn about teen acne on face, chest, shoulders, back & how AKLIEF® (trifarotene) Cream, 0.005% can help. See safety info
Efficacy - Clinical Trials | AKLIEF® (trifarotene) Cream HCP
SATISFY Study: A multicenter, open-label study of 453 patients with moderate facial and truncal acne assessing the long-term safety (primary endpoint), efficacy, and quality of life (secondary …